- In March 2026, Sallie Mae announced expanded graduate loan options for medical and dental students, including industry-first grace periods of up to 96 months for eligible medical borrowers, broader credit eligibility, and flexible in-school repayment choices covering up to 100% of school-certified costs.
- The move deepens Sallie Mae’s presence in advanced health care education finance, pairing longer repayment timelines with tailored support teams, scholarship tools, and residency-friendly deferment features that could reshape how future doctors and dentists manage education-related debt.
- We’ll now examine how Sallie Mae’s extended grace periods and tailored medical and dental loan features may influence its overall investment narrative.
Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
SLM Investment Narrative Recap
To own SLM, you generally need to believe its private education lending model can stay profitable despite regulatory shifts, credit cycles, and funding costs. The new extended-grace medical and dental loans deepen its niche in graduate health care lending, but they do not clearly change the most immediate swing factors: credit performance in existing portfolios and access to reasonably priced capital for funding originations.
The most relevant recent development alongside this product launch is SLM’s ongoing share repurchase program, with about US$623.7 million spent retiring roughly 11.5 percent of shares by late 2025. Together, an expanded graduate franchise and continued buybacks frame the current debate around balancing growth in specialized lending with disciplined credit risk and capital flexibility.
Yet, while these expanded medical and dental loans may look attractive, investors should be aware that...
Read the full narrative on SLM (it's free!)
SLM’s narrative projects $1.5 billion revenue and $658.4 million earnings by 2029.
Uncover how SLM's forecasts yield a $30.73 fair value, a 49% upside to its current price.
Exploring Other Perspectives
More pessimistic analysts were already assuming earnings drift toward about US$554.0 million by 2028, so if you worry about concentrated graduate lending risk, their view offers a sharper contrast worth exploring.
Explore 2 other fair value estimates on SLM - why the stock might be worth as much as 73% more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your SLM research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
- Our free SLM research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SLM's overall financial health at a glance.
Contemplating Other Strategies?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com